XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
  Autoimmune Diseases
  Immunosupressants
  Monoclonal Antibodies
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Sep 21st, 2006 - 20:28:32

The New England Journal of Medicine

Immunology Channel
subscribe to Immunology newsletter

Latest Research : Immunology

   DISCUSS   |   EMAIL   |   PRINT
Leeds University study shows eculizumab may be an effective therapy for PNH
Sep 21, 2006, 20:23, Reviewed by: Dr. Rashmi Yadav

"These study results suggest that eculizumab has great potential in providing patients diagnosed with PNH with an effective therapy."

 
A study led by Dr Peter Hillmen of the Leeds Teaching Hospitals NHS Trust, relating to an uncommon and severe haemolytic anaemia known as paroxysmal nocturnal haemoglobinuria (PNH), was published in the current issue of The New England Journal of Medicine. In the Phase III efficacy study, TRIUMPH, 87 patients were treated at 34 sites in the U.S., Canada, Europe, and Australia. The data showed clinically significant improvements in anaemia and the quality of life for patients with PNH.

The study was a double-blind, randomized, placebo-controlled trial that tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against complement protein C5, that inhibits terminal complement activation. Patients received either placebo or eculizumab intravenously. Eculizumab treatment significantly improved anaemia in patients as both primary endpoints were achieved, including median transfusion rate and haemoglobin stabilization over six months. The median transfusion rate was reduced from 10 units per patient with placebo to 0 units per patient with eculizumab (p<0<0
 

- The results are published in the current issue of The New England Journal of Medicine
 

http://www.noonanrusso.com/

 
Subscribe to Immunology Newsletter
E-mail Address:

 



Related Immunology News

Pregnant women with lupus are at higher risk for complications
Molecular 'signature' protects cells from viruses
Discovery in the evolution of the immune system absorbing cells
Leeds University study shows eculizumab may be an effective therapy for PNH
Research Reveals Inner Workings of Immune System “Thermostat”
CD23 Protein in Stool Samples may Indicate Food Allergy
Molecular signals triggering maturation of natural killer cells uncovered
New method to analyse the Major Histocompatibility Complex (MHC) of the human genome
Front Line Immune Cells Mature in Four Stages - Study
Caspase-12 gene that shuts down immune system is found in 20% of people of African descent


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us